Switch to:
More From Other Websites
Appendix 4E and Full Year Statutory Accounts Aug 30 2016
Novogen appoints Key Management Personnel to drive transition to a development-focused organisation Aug 28 2016
Novogen Submits IND Application to the US FDA for Cantrixil in Ovarian Cancer Aug 14 2016
Novogen Submits Investigational New Drug (IND) Application to the US FDA For Cantrixil(TM) in... Aug 11 2016
Novogen Patent Covering Anisina(TM) Has Proceeded to Grant Jun 13 2016
Novogen Patent Covering Anisina Has Proceeded to Grant Jun 13 2016
Edison Investment Research Report maintains valuation as Novogen resumes 100% ownership of Cantrixil May 09 2016
Novogen Provides Update On Development Of Cantrixil May 01 2016
Novogen Provides Update on Development of Cantrixil May 01 2016
Cantrixil (TRXE-002-1) Abstract (AACR Annual Meeting 2016) Apr 17 2016
Novogen Receives R&D Tax Incentive Cash Refund Mar 16 2016
Novogen Patent Covering Cantrixil And Trilexium Has Proceeded To Grant Feb 19 2016
Novogen Announces Changes to the Board with New Chairman and Deputy Chairman Appointed Feb 05 2016
Letter to Shareholders from CEO James Garner Jan 31 2016
Novogen appoints new CEO Dec 09 2015
Novogen Appoints Dr James Garner as Chief Executive Officer Dec 09 2015
NOVOGEN LTD Financials Dec 08 2015
Novogen Engages Contract Research Organisation to Conduct Cantrixil Phase 1 Clinical Trial Nov 23 2015
Novogen Patent Covering Cantrixil and Trilexium Accepted in Australia Nov 11 2015
Preclinical Studies Justify Mode of Delivery and Dosing Regimen for Anisina Nov 10 2015


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK